Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels

PHIO
Phio Pharmaceuticals Corp. Common Stock
stock NASDAQ

At Close
May 8, 2025 3:59:30 PM EDT
1.81USD-11.275%(-0.23)90,898
0.00Bid   0.00Ask   0.00Spread
Pre-market
May 9, 2025 9:28:30 AM EDT
1.78USD-1.111%(-0.02)40,390
After-hours
May 8, 2025 4:39:30 PM EDT
1.78USD-1.657%(-0.03)11,302
OverviewPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 11, 2022
07:40AM EST  Phio Pharma Announces Regulatory Clearance Of Clinical Trial For PH-762 To Treat Melanoma   RTTNews
07:31AM EST  Phio Pharmaceuticals Announces French Regulatory Clearance of Clinical Trial for PH-762 to Treat Melanoma   Benzinga
07:31AM EST  Phio Pharmaceuticals Announces Regulatory Clearance of Clinical Trial for   PR Newswire
Jan 3, 2022
07:30AM EST  Phio Pharmaceuticals Scheduled to Participate in the H.C. Wainwright Virtual   PR Newswire
Nov 12, 2021
07:05AM EST  Phio Pharma Presents Positive New Data On Systemic Immune Response After Local PH-762 Therapy At SITC Annual Meeting   RTTNews
07:01AM EST  Phio Pharmaceuticals Presents Positive New Data On Systemic Immune Response   PR Newswire
Nov 10, 2021
06:22PM EST  Phio Pharmaceuticals Reports Q3 2021 Operating Expenses $3.739M Vs $2.3M YoY   Benzinga
04:40PM EST  Phio Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides   PR Newswire
Oct 18, 2021
07:13AM EDT  Phio Pharmaceuticals Announces Upcoming Presentation At SITC 36th Annual Meeting Nov. 10-14   Benzinga
07:05AM EDT  Phio Pharmaceuticals Announces Upcoming Presentation at the SITC 36th Annual   PR Newswire
Oct 7, 2021
09:20AM EDT  Phio Pharmaceuticals Presents New BRD4 Data On Molecular Targets And Cancer Therapeutics   RTTNews
09:19AM EDT  Phio Pharmaceuticals Presents New BRD4 Data At AACR-NCI-EORTC International Conference   Benzinga
09:05AM EDT  Phio Pharmaceuticals Presents New BRD4 Data at the AACR-NCI-EORTC International   PR Newswire
Sep 30, 2021
08:05AM EDT  Phio Pharmaceuticals Announces Two Upcoming Data Presentations at Scientific   PR Newswire
Sep 16, 2021
07:48AM EDT  The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study   Benzinga
07:06AM EDT  Phio Pharma Highlights Data Presentation For European Society Of Medical Oncology   Benzinga
07:05AM EDT  Phio Pharmaceuticals Presents Data at ESMO 2021 Demonstrating Persistent   PR Newswire
Sep 3, 2021
07:06AM EDT  Phio Pharmaceuticals to Participate in the H.C. Wainwright 23rd Annual Global   PR Newswire
Aug 31, 2021
08:09AM EDT  Phio Pharmaceuticals To Present Data At European Society of Medical Oncology Virtual Congress 2021 Sept. 16-21   Benzinga
08:06AM EDT  Phio Pharmaceuticals Announces Upcoming Data Presentation At ESMO Virtual Congress 2021   Benzinga
08:05AM EDT  Phio Pharmaceuticals Announces Upcoming Data Presentation at the ESMO Virtual   PR Newswire
Aug 18, 2021
07:38AM EDT  The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline   Benzinga
Aug 17, 2021
08:28AM EDT  The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business   Benzinga
Aug 12, 2021
05:28PM EDT  Phio Pharmaceuticals Q2 EPS $(0.20) Up From $(0.34) YoY   Benzinga
05:00PM EDT  Phio Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides   PR Newswire
Aug 9, 2021
11:20AM EDT  Phio Pharmaceuticals Granted European Patent Titled 'RNA INTERFERENCE IN OCULAR INDICATIONS'   Benzinga
Jul 20, 2021
08:20AM EDT  The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street   Benzinga
Jul 7, 2021
04:30PM EDT  Phio Pharmaceuticals Scheduled to Participate in a Fireside Chat with H.C.   PR Newswire
Jun 22, 2021
11:05AM EDT  Phio Pharmaceuticals Reschedules Fireside Chat Hosted by H.C. Wainwright for   PR Newswire
Jun 14, 2021
09:32AM EDT  10 Biggest Price Target Changes For Monday   Benzinga
08:01AM EDT  Phio Pharmaceuticals Scheduled to Participate in Two Upcoming Investor Events   PR Newswire
06:24AM EDT  HC Wainwright & Co. Maintains Buy on Phio Pharmaceuticals, Raises Price Target to $6   Benzinga
Jun 9, 2021
11:35AM EDT  Phio Pharmaceuticals Shares See Volume; Co Granted European Patent Titled 'RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS'   Benzinga
Jun 4, 2021
08:07AM EDT  Phio Pharmaceuticals Presents New In Vivo Data at the 2021 ASCO Annual Meeting Showing Dual-Targeting INTASYL Offers Increased Efficacy and Safety Potential Over Other Therapeutic Approaches   Benzinga
08:01AM EDT  Showing Dual-Targeting INTASYL Offers Increased Efficacy and Safety Potential Over Other Therapeutic Approaches   PR Newswire
Jun 1, 2021
10:13AM EDT  Phio Pharmaceuticals Granted U.S. Patent Titled 'Reduced size self-delivering nucleic acid compounds targeting long non-coding RNA'   Benzinga
May 18, 2021
07:44AM EDT  The Daily Biotech Pulse: Spero Secures NIAID Funding, GlaxoSmithKline Releases COVID-19 Data, BioNTech Gets New CFO   Benzinga
May 14, 2021
07:59AM EDT  The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts   Benzinga
May 13, 2021
05:25PM EDT  Phio Pharmaceuticals Q1 EPS $(0.32) Up From $(1.33) YoY   Benzinga
05:00PM EDT  Phio Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides   PR Newswire
May 11, 2021
01:10PM EDT  Phio Pharma's PH-762 Shows Encouraging Antitumor Efficacy In Preclinical Studies   Benzinga
09:35AM EDT  Phio Pharma Shares Quiet; Co Granted U.S. Patent Titled 'Nucleic acid molecules targeting superoxide dismutase 1 (SOD1)'   Benzinga
09:12AM EDT  Phio Pharma Reports New In Vivo Data Showing PH-762 'Significantly' Enhanced Antitumor Efficacy Of HER2-Targeted CAR-T Cells In Solid Tumors   Benzinga
08:47AM EDT  Phio Announces Positive New In Vivo Data Showing That PH-762 Enhance Antitumor Efficacy Of HER2CART In Solid Tumors   RTTNews
08:02AM EDT  Phio Pharmaceuticals Presents Positive In Vivo Data at ASGCT Showing PH-762   PR Newswire
Apr 29, 2021
07:58AM EDT  Phio Pharmaceuticals Announces Upcoming Data Presentations At ASGCT And ASCO Annual Meetings   Benzinga
07:31AM EDT  Phio Pharmaceuticals Announces Upcoming Data Presentations at the ASGCT and   PR Newswire
Apr 12, 2021
10:12AM EDT  Phio Pharma Saturday Morning Announced Presentation Of In Vivo Data Showing Strong Tumor Control For Intratumoral Delivery Of INTASYL RNAi Targeting PD-1 At American Association For Cancer Research Conference   Benzinga
07:33AM EDT  Phio Pharma's Intasyl Platform Shows Promising Tumor Control Activity In Animal Studies   Benzinga
Apr 10, 2021
08:31AM EDT  Phio Pharmaceuticals Presents Positive In Vivo Data Showing Strong Tumor   PR Newswire
Mar 30, 2021
10:17AM EDT  Phio Pharmaceuticals Shares See Volume; Co Received Intention To Grant European Patent Titled 'RNA INTERFERENCE IN OCULAR INDICATIONS'   Benzinga
Mar 26, 2021
07:28AM EDT  The Daily Biotech Pulse: FDA Nod For Astellas, Seagen, Gilead Get Positive Regulatory Tidings From Europe, 3 IPOs   Benzinga
Mar 25, 2021
05:17PM EDT  Phio Pharmaceuticals FY20 EPS $(1.92) vs $(19.33) In FY19   Benzinga
05:15PM EDT  Phio Pharmaceuticals Reports 2020 Year End Financial Results and Provides   PR Newswire
Mar 11, 2021
07:39AM EST  Phio Pharmaceuticals To Present New Data On PD-1 Targeting INTASYL At The 2021 AACR Annual Meeting   RTTNews
07:36AM EST  Phio Pharmaceuticals To Present New Data On PD-1 Targeting INTASYL At The 2021 American Association For Cancer Research Annual Meeting   Benzinga
07:31AM EST  Phio Pharmaceuticals To Present New Data on PD-1 Targeting INTASYL at the 2021   PR Newswire
Mar 2, 2021
09:58AM EST  Phio Pharmaceuticals Shares Quiet; Co Granted U.S. Patent Titled 'Immunotherapy of cancer'   Benzinga
Mar 1, 2021
09:01AM EST  Phio Pharma Shares Are Trading Higher On Cancer Immunotherapies Pact With AgonOx   Benzinga
08:12AM EST  Phio Pharmaceuticals Corp. (PHIO) has entered into a clinical development collaboration with AgonOx, Inc. to develop T cell-based cancer immunotherapies using Phio's lead INTASYL based product candidate PH-762 and AgonOx's DP tumor-infiltrating lymphocyte technology. The study is expected to start enrolling patients later in the current year.   RTTNews
08:05AM EST  Phio Pharmaceuticals And AgonOx, Inc. Announce Collaboration On Clinical Development Of Novel T Cell-based Cancer Immunotherapies; Financial Details Not Disclosed   Benzinga
08:03AM EST  Phio Pharma And AgonOx Collaborate On Clinical Development Of Novel T Cell-based Cancer Immunotherapies   RTTNews
08:01AM EST  Phio Pharmaceuticals and AgonOx, Inc. Announce Collaboration on Clinical   PR Newswire
Feb 23, 2021
07:31AM EST  Phio Pharmaceuticals to Participate in the H.C. Wainwright Global Life Sciences   PR Newswire
Feb 17, 2021
04:16PM EST  Phio Pharmaceuticals Announces Closing of $7.7 Million Registered Direct   PR Newswire
Feb 16, 2021
10:26AM EST  Phio Pharmaceuticals To Be Issued U.S. Patent Titled 'IMMUNOTHERAPY OF CANCER'   Benzinga
Feb 12, 2021
07:03AM EST  Phio Pharma Prices ~2.25M Share Offering At $3.42/Share   Benzinga
07:03AM EST  Phio Pharmaceuticals Announces $7.7 Mln Registered Direct Offering Of Common Stock Priced At-the-Market   RTTNews
07:01AM EST  Phio Pharmaceuticals Announces $7.7 Million Registered Direct Offering of   PR Newswire
Feb 1, 2021
02:01PM EST  Phio Pharmaceuticals Received A Notice Of Allowance From U.SS Patent And Trademark Office Titled 'REDUCED SIZE SELF-DELIVERING NUCLEIC ACID COMPOUNDS TARGETING LONG NON-CODING RNA'   Benzinga
Jan 26, 2021
05:26AM EST  Phio Pharmaceuticals Awarded U.S. Patent #10,900,03 'Methods for treating aging and skin disorders using nucleic acids targeting Tyr or MMP1'   Benzinga
Jan 25, 2021
05:23PM EST  Phio Pharmaceuticals Reports Closing Of $14.0 Mln Private Placement   RTTNews
05:15PM EST  Phio Pharmaceuticals Announces Closing of $14.0 Million Private Placement   PR Newswire
Jan 21, 2021
03:34PM EST  Phio Pharma Prices ~4.56M Common Stock Offering At $3.07/Share   Benzinga
03:34PM EST  Phio Pharmaceuticals Announces $14.0 Million Private Placement Priced   PR Newswire
Jan 4, 2021
04:15PM EST  Phio Pharmaceuticals to Participate in the H.C. Wainwright BioConnect 2021   PR Newswire
Dec 29, 2020
05:37AM EST  Phio Pharmaceuticals Issued U.S Patent 10,876,119 'Reduced size self-delivering RNAI compounds'   Benzinga
Nov 23, 2020
11:22AM EST  Phio Pharmaceuticals Granted European Patent Titled 'NUCLEIC ACID MOLECULES TARGETING SUPEROXIDE DISMUTASE 1 (SOD1)'   Benzinga
Nov 19, 2020
07:30AM EST  Phio Pharmaceuticals to Participate in the 3rd Annual Evercore ISI HealthCONx   PR Newswire
Nov 10, 2020
05:02PM EST  Phio Pharmaceuticals Q3 Loss/share $0.40 Vs. Loss $4.53 Year Ago   RTTNews
05:00PM EST  Phio Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides   PR Newswire
Nov 9, 2020
08:08AM EST  Phio Announces Positive In Vivo Data On Combination PD-1 And TIGIT Checkpoint Blockade With INTASYL In A Single Therapeutic For Cancer Treatment   Benzinga
08:02AM EST  Phio Announces Positive In Vivo Data On Combination PD-1 And TIGIT Checkpoint   PR Newswire
Oct 26, 2020
07:48AM EDT  Phio Pharma Announces Three Poster Presentations At SITC Annual Meeting   RTTNews
07:42AM EDT  Phio Pharmaceuticals Announces Three Poster Presentations At 2020 Society For Immunotherapy Of Cancer Annual Meeting   Benzinga
07:31AM EDT  Phio Pharmaceuticals Announces Three Poster Presentations at the 2020 Society   PR Newswire
Oct 20, 2020
09:24AM EDT  Phio Pharmaceuticals Shares Tick Higher; Co Granted U.S. Patented No. 10,808,247 Titled 'Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach'   Benzinga
Sep 9, 2020
07:05AM EDT  Phio Pharmaceuticals to Present at the H.C. Wainwright 22nd Annual Global   PR Newswire
Aug 12, 2020
05:01PM EDT  Phio Pharmaceuticals Q2 EPS $(0.34) Down From $(0.08) YoY   Benzinga
05:00PM EDT  Phio Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides   PR Newswire
Aug 5, 2020
09:32AM EDT  Benzinga's Top Upgrades, Downgrades For August 5, 2020   Benzinga
06:14AM EDT  HC Wainwright & Co. Initiates Coverage On Phio Pharmaceuticals with Buy Rating, Announces Price Target of $4   Benzinga


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC